Immunoassays exhibiting reduced cross-reactivity with hydrophobic drug analyte metabolites

US8288111B2 · kind B2 · utility

Assignee

• Abbott Laboratories · US

Inventors

• Elaine M. Brate · Grayslake, US
• David M. Finley · Spring Grove, US
• Shelley R. Holets-McCormack · Waukegan, US
• David Pacenti · Libertyville, US
• Ryan E. Piktel · Waukegan, US
• Michelle L. Shields · Palos Park, US
• Thomas G. Spring · Highland Park, US
• Phillip P. Wang · Libertyville, US

Key dates

• Filing date: May 23, 2008
• Grant date: Oct 16, 2012
• Expiry date: Nov 23, 2028

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N33/9493
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present disclosure provides among other things immunoassays exhibiting reduced cross-reactivity with analyte metabolites. Additionally, the present disclosure provides diagnostic immunoassays to determine the concentration or level in a test sample of a hydrophobic drug that metabolizes in vivo or in vitro to form cross-reacting metabolites wherein cross-reactivity with such metabolites of the drug analyte is reduced. In particular, the disclosure provides such immunoassays where the hydrophobic drug is an immunosuppressant drug such as cyclosporine A.